Nivolumab

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13351 publications

Olive Oil-Based Lipid Emulsion Ameliorates Immune Checkpoint Inhibitor-Induced Myocarditis via Inhibition of the NF-κB/NLRP3/IL-1β Pathway.

Olive Oil-Based Lipid Emulsion Ameliorates Immune Checkpoint Inhibitor-Induced Myocarditis via Inhibition of the NF-κB/NLRP3/IL-1β Pathway.

Journal: Journal of visualized experiments : JoVE
Published: June 22, 2026

Data support longer recurrence-free survival with nivolumab than with ipilimumab for stage III or IV melanoma.

Data support longer recurrence-free survival with nivolumab than with ipilimumab for stage III or IV melanoma.

Journal: CA: a cancer journal for clinicians
Published: June 22, 2026

Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.

Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.

Journal: Oncoimmunology
Published: June 20, 2026

Anti-striated muscle antibody positive anti-PD-1 antibody related myositis and cardiomyositis: an instructive autopsy case report with discussion for trigger of irAE.

Anti-striated muscle antibody positive anti-PD-1 antibody related myositis and cardiomyositis: an instructive autopsy case report with discussion for trigger of irAE.

Journal: Immunological medicine
Published: June 18, 2026

Diefenbach CS, Jegede O, Wang V, et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026;147(18):2041-2052.

Diefenbach CS, Jegede O, Wang V, et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026;147(18):2041-2052.

Journal: Blood
Published: June 18, 2026

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: June 18, 2026

ASO Visual Abstract: Clinical Outcomes of First-Line Immune Checkpoint Inhibitor-Based Therapy for Postoperative Recurrence After Adjuvant Nivolumab in Esophageal Cancer.

ASO Visual Abstract: Clinical Outcomes of First-Line Immune Checkpoint Inhibitor-Based Therapy for Postoperative Recurrence After Adjuvant Nivolumab in Esophageal Cancer.

Journal: Annals of surgical oncology
Published: June 17, 2026

Development of a Digital Phenotype for Immune-Related Colitis.

Development of a Digital Phenotype for Immune-Related Colitis.

Journal: JCO clinical cancer informatics
Published: June 16, 2026

Autoantibodies Drive Fcγ Receptor-Dependent Colon Inflammation During Immune Checkpoint Blockade.

Autoantibodies Drive Fcγ Receptor-Dependent Colon Inflammation During Immune Checkpoint Blockade.

Journal: bioRxiv : the preprint server for biology
Published: June 12, 2026

Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report.

Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report.

Journal: Clinical advances in hematology & oncology : H&O
Published: June 12, 2026

Methodological considerations in a real-world study of first-line nivolumab plus ipilimumab for metastatic renal cell carcinoma.

Methodological considerations in a real-world study of first-line nivolumab plus ipilimumab for metastatic renal cell carcinoma.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: June 11, 2026

Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study.

Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study.

Journal: Pakistan journal of pharmaceutical sciences
Published: June 09, 2026
Showing 1-12 of 13,351

Last Updated: 06/30/2026